Trial site
Santa Casa de Misericordia de Belo Horizonte
- 16running trials
- 6closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- Lupus (SLE)5 trials
- Chronic kidney disease2 trials
- Coronary artery disease2 trials
- Lung cancer2 trials
- Multiple myeloma2 trials
- Obesity2 trials
- Peripheral artery disease2 trials
- Bladder cancer1 trial
- Colorectal cancer1 trial
- Gout1 trial
- Heart failure1 trial
- Idiopathic pulmonary fibrosis1 trial
- and 4 more
- Phase
- Phase 312 trials
- Phase 25 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Status
- Active, not recruiting9 trials
- Recruiting6 trials
- Completed4 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- Biogen4 trials
- Amgen1 trial
- Bristol-Myers Squibb1 trial
- CSL Behring1 trial
- and 10 more
Running trials
Recruiting
Active, not recruiting
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Recruiting
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Recruiting
Active, not recruiting
Active, not recruiting
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Active, not recruiting
Enrolling by invitation
Active, not recruiting
Active, not recruiting
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Chronic kidney disease1 recruiting
- Colorectal cancer1 recruiting
- Coronary artery disease1 recruiting
- Lung cancer1 recruiting
- Lupus (SLE)1 recruiting
- Peripheral artery disease1 recruiting
- Psoriatic arthritis1 recruiting
Closed trials
Terminated
Completed
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Completed
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Completed
Completed
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Terminated
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Site data: ClinicalTrials.govUpdated 18 Nov 2026